ADENOCARCINOMA PANCREAS

This adverse event was reported 1285 times

These drugs are most commonly taken by patients reporting ADENOCARCINOMA PANCREAS:

# Drug Count
0 SITAGLIPTIN 250
1 EXENATIDE 157
2 METFORMIN 145
3 METFORMIN ER 500 MG 133
4 METFORMIN ER 750 MG 133
5 LIRAGLUTIDE 118
6 SITAGLIPTIN AND METFORMIN HYDROCHLORIDE 104
7 INSULIN GLARGINE 102
8 GEMCITABINE HYDROCHLORIDE 99
9 GEMCITABINE 89
See all common drugs associated with ADENOCARCINOMA PANCREAS

ADENOCARCINOMA PANCREAS is most prevalent among patients taking these drugs:

# Drug Count Frequency
0 PACKERA AUREA 1 0.5000
1 ADALIMUMAB-AQVH 1 0.0101
2 PRAMLINTIDE ACETATE 1 0.0098
3 ALITRETINOIN 1 0.0084
4 ALUMINUM HYDROXIDE GEL 1 0.0068
5 SITAGLIPTIN AND METFORMIN HYDROCHLORIDE 104 0.0048
6 ACID REDUCER 1 0.0039
7 SITAGLIPTIN 250 0.0035
8 EXENATIDE 157 0.0030
9 INTERLEUKIN-10 1 0.0028
See all drugs enriched for association with ADENOCARCINOMA PANCREAS

ADENOCARCINOMA PANCREAS is most prevalent among patients taking these drug classes:

# Drug class Count Frequency
0 Leptin Analog [EPC] 2 0.0016
1 Serotonin-4 Receptor Agonist [EPC] 1 0.0015
2 Sulfonamide Antibacterial [EPC] 6 0.0015
3 Provitamin D2 Compound [EPC] 31 0.0010
4 CCR5 Co-receptor Antagonist [EPC] 2 0.0009
5 CD38-directed Cytolytic Antibody [EPC] 5 0.0009
6 Enzyme Stabilizer [EPC] 1 0.0009
7 Antihypoglycemic Agent [EPC] 3 0.0007
8 GLP-1 Receptor Agonist [EPC] 295 0.0007
9 Sulfonylurea [EPC] 70 0.0006
See all drug classes enriched for association with ADENOCARCINOMA PANCREAS